Neuronal death in Alzheimer's disease and therapeutic opportunities

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 11-12, 2009, Pages 4329-4348

  Donev, Rossen ^a   Kolev, Martin ^a   Millet, Bruno ^b   Thome, Johannes ^c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid plaques; Neurodegeneration; Neuronal death; Neuroprotection; Neurotoxicity

Indexed keywords

ALZHEIMER DISEASE; ANIMAL; ARTICLE; CELL DEATH; HUMAN; NERVE CELL; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; CELL DEATH; HUMANS; NEURONS;

EID: 77951150250     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00889.x     Document Type: Article

References (258)

1. Tana S. Alzheimer's disease - opportunities to address pharmaceutical gaps. Priority medicines for Europe and the world - A public health approach to innovation 2004, 3-6. Kaplan WLaing R. In, editors, Geneva (Switzerland), World Health Organization, pp
2. Bertram L, McQueen M, Mullin K. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007, 39:17-23.
3. Carter C. Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem Int. 2007, 50:12-38.
4. Selkoe D. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis. 2001, 3:75-80.
5. Prasad K, Cole W, Prasad K. Risk factors for Alzheimer's disease: role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment. J Am Coll Nutr. 2002, 21:506-22.
6. Rich J, Rasmusson D, Folstein M. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 1995, 45:51-5.
7. Akiyama H, Barger S, Barnum S. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000, 21:383-421.
8. Bradt B, Kolb W, Cooper N. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med. 1998, 188:431-8.
9. Breitner J, Welsh K, Helms M. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging. 1995, 16:523-30.
10. Breitner J, Gau B, Welsh K. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. 1994, 44:227-32.
11. Andersen K, Launer L, Ott A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology. 1995, 45:1441-5.
12. Myllykangas-Luosujärvi R, Isomäki H. Alzheimer's disease and rheumatoid arthritis. Br J Rheumatol. 1994, 33:501-2.
13. McGeer P, Schulzer M, McGeer E. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology. 1996, 47:425-32.
14. Rogers J, Kirby L, Hempelman S. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993, 43:1609-11.
15. Sharif S, Hariri R, Chang V. Human astrocyte production of tumour necrosis factor-alpha, interleukin-1 beta, and interleukin-6 following exposure to lipopolysaccharide endotoxin. Neurol Res. 1993, 15:109-12.
16. Shalit F, Sredni B, Stern L. Elevated interleukin-6 secretion levels by mononuclear cells of Alzheimer's patients. Neurosci Lett. 1994, 174:130-2.
17. Kolev M, Ruseva M, Harris C. Implication of complement system and its regulators in Alzheimer's disease. Curr Neuropharmacol. 2009, 7:1-8.
18. Anderton B. Free radicals on the mind. Hydrogen peroxide mediates amyloid beta protein toxicity. Hum Exp Toxicol. 1994, 13:716-9.
19. Chen L, Richardson J, Caldwell J. Regional brain activity of free radical defense enzymes in autopsy samples from patients with Alzheimer's disease and from nondemented controls. Int J Neurosci. 1994, 75:83-90.
20. Rozemuller J, Eikelenboom P, Pals S. Microglial cells around amyloid plaques in Alzheimers disease express leukocyte adhesion molecules of the LFA-1 family. Neurosci Lett. 1989, 101:288-92.
21. Verbeek M, Otteholler I, Westphal J. Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimers disease. Am J Pathol. 1994, 144:104-16.
22. Prasad K, Hovland A, La Rosa F. Prostaglandins as putative neurotoxins in Alzheimer's disease. Proc Soc Exp Biol Med. 1998, 219:120-5.
23. Lue L, Rydel R, Brigham E. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia. 2001, 35:72-9.
24. Smits H, Rijsmus A, van Loon J. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J Neuroimmunol. 2002, 127:160-8.
25. Heneka M, Galea E, Gavriluyk V. Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. J Neurosci. 2002, 22:2434-42.
26. Joachim C, Selkoe D. The seminal role of beta-amyloid in the pathogenesis of Alzheimer disease. Alzheimer Dis Assoc Disord. 1992, 6:7-34.
27. Selkoe D. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol. 1994, 10:373-403.
28. Wang G, Khatoon S, Iqbal K. Brain ubiquitin is markedly elevated in Alzheimer disease. Brain Res. 1991, 566:146-51.
29. Kudo T, Iqbal K, Ravid R. Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels. Brain Res. 1994, 639:1-7.
30. Checler F, da Costa C, Ancolio K. Role of the proteasome in Alzheimer's disease. Biochim Biophys Acta. 2000, 1502:133-8.
31. Rockwell P, Yuan H, Magnusson R. Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2). Arch Biochem Biophys. 2000, 374:325-33.
32. Gregori L, Hainfeld J, Simon M. Binding of amyloid beta protein to the 20 S proteasome. J Biol Chem. 1997, 272:58-62.
33. Mackenzie I. Anti-inflammatory drugs and Alzheimer-type pathology in aging. Neurology. 2000, 54:732-4.
34. Weggen S, Eriksen J, Das P. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001, 414:212-6.
35. Bate C, Veerhuis R, Eikelenboom P. Neurones treated with cyclo-oxygenase-1 inhibitors are resistant to amyloid-beta1-42. Neuroreport. 2003, 14:2099-103.
36. Shaftel S, Griffin W, O'Banion M. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation 10.1186/1742-2094-5-7, DOI
37. Oprica M, Hjorth E, Spulber S. Studies on brain volume, Alzheimer-related proteins and cytokines in mice with chronic overexpression of IL-1 receptor antagonist. J Cell Mol Med. 2007, 11:810-25.
38. Selkoe D, Schenk D. Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol. 2003, 43:545-84.
39. Morishima M, Ihara Y. Posttranslational modifications of tau in paired helical filaments. Dementia. 1994, 5:282-8.
40. Caughey B, Lansbury P. Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003, 26:267-98.
41. Gschwind M, Huber G. Apoptotic cell death induced by beta-amyloid(1-42) peptide is cell type dependent. J Neurochem. 1995, 65:292-300.
42. Vincent B, Cisse M, Sunyach C. Regulation of betaAPP and PrPc cleavage by alpha-secretase: mechanistic and therapeutic perspectives. Curr Alzheimer Res. 2008, 5:202-11.
43. Brunkan A, Goate A. Presenilin function and gamma-secretase activity. J Neurochem. 2005, 93:769-92.
44. Wolfe M, Xia W, Ostaszewski B. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999, 398:513-7.
45. De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron. 2003, 38:9-12.
46. Haass C. Take five-BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J. 2004, 23:483-8.
47. Borchelt D, Thinakaran G, Eckman C. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 1996, 17:1005-13.
48. Rogaev E, Sherrington R, Rogaeva E. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995, 376:775-8.
49. Scheuner D, Eckman C, Jensen M. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996, 2:864-70.
50. De Strooper B, Saftig P, Craessaerts K. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998, 391:387-90.
51. Mastrangelo P, Mathews P, Chishti M. Dissociated phenotypes in presenilin transgenic mice define functionally distinct gamma-secretases. Proc Natl Acad Sci USA. 2005, 102:8972-7.
52. Popescu B, Ankarcrona M. Neurons bearing presenilins: weapons for defense or suicide. J Cell Mol Med. 2000, 4:249-61.
53. Cowburn R, Popescu B, Ankarcrona M. Presenilin-mediated signal transduction. Physiol Behav. 2007, 92:93-7.
54. Canevari L, Abramov A, Duchen M. Toxicity of amyloid beta peptide: Tales of calcium, mitochondria, and oxidative stress. Neurochem Res. 2004, 29:637-50.
55. LaFerla F. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci. 2002, 3:862-72.
56. Morishima Y, Gotoh Y, Zieg J. beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci. 2001, 21:7551-60.
57. Lee M, Kwon Y, Li M. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 2000, 405:360-4.
58. Bozyczko-Coyne D, O'Kane T, Wu Z. CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with A beta-induced cortical neuron apoptosis. J Neurochem. 2001, 77:849-63.
59. Morishima-Kawashima M, Oshima N, Ogata H. Effect of apolipoprotein E allele epsilon 4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am J Pathol. 2000, 157:2093-9.
60. Mucke L, Masliah E, Yu G. High-level neuronal expression of A beta(1-42) in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci. 2000, 20:4050-8.
61. Lue L, Kuo Y, Roher A. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999, 155:853-62.
62. Walsh D, Lomakin A, Benedek G. Amyloid beta-protein fibrillogenesis - Detection of a protofibrillar intermediate. J Biol Chem. 1997, 272:22364-72.
63. Lambert M, Barlow A, Chromy B. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998, 95:6448-53.
64. Wang H, Pasternak J, Kuo H. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 2002, 924:133-40.
65. Klein W. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int. 2002, 41:345-52.
66. Shankar G, Li S, Mehta T. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008, 14:837-42.
67. Naylor R, Hill A, Barnham K. Is covalently crosslinked Abeta responsible for synaptotoxicity in Alzheimer's disease. Curr Alzheimer Res. 2008, 5:533-9.
68. Asghar S, Pasch M. Therapeutic inhibition of the complement system. Y2K update. Front Biosci 2000, 5:E63-81.
69. Silva C, Rio M, Cruz C. Local immunoglobulin synthesis and blood-brain barrier assessment in subacute sclerosing panencephalitis. Eur Neurol. 1985, 24:128-33.
70. Barnum S. Complement biosynthesis in the central nervous system. Crit Rev Oral Biol Med. 1995, 6:132-46.
71. Emmerling MR, Watson MD, Raby CA. The role of complement in Alzheimer's disease pathology. Bichemica et Biophysica Acta. 2000, 1502:158-71.
72. Gasque P, Fontaine M, Morgan B. Complement expression in human brain - biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J Immunol. 1995, 154:4726-33.
73. Vedeler C, Ulvestad E, Bjorge L. The expression of CD59 in normal human nervos tissue. Immunol. 1994, 82:542-7.
74. Pasinetti G, Johnson S, Oda T. Clusterin (SGP-2) - a multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain. J Comp Neurol. 1994, 339:387-400.
75. Yang L, Li R, Meri S, Rogers J. Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J Neurosci. 2000, 20:7505-9.
76. Osaka H, Mukherjee P, Aisen P. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem. 1999, 73:303-11.
77. Pasinetti G. Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: the role of the complement system. Neurobiol Aging. 1996, 17:707-16.
78. Wyss-Coray T, Yan F, Lin A. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci USA. 2002, 99:10837-42.
79. Pisalyaput K, Tenner A. Complement component C1q inhibits beta-amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. J Neurochem. 2008, 104:696-707.
80. Maier M, Peng Y, Jiang L. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci. 2008, 28:6333-41.
81. Gasque P, Thomas A, Fontaine M. Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. J Neuroimmunol. 1996, 66:29-40.
82. Sano M, Ernesto C, Thomas R. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997, 336:1216-22.
83. Birkmayer J. Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type. Ann Clin Lab Sci. 1996, 26:1-9.
84. Misonou H, Morishima-Kawashima M. Oxidative stress induces intracellular accumulation of amyloid beta-protein (A beta) in human neuroblastoma cells. Biochemistry. 2000, 39:6951-9.
85. Koppaka V, Axelsen P. Accelerated accumulation of amyloid beta proteins on oxidatively damaged lipid membranes. Biochemistry. 2000, 39:10011-6.
86. Schubert D, Behl C, Lesley R. Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci USA. 1995, 92:1989-93.
87. Behl C, Davis J, Cole G. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem Biophys Res Commun. 1992, 186:944-50.
88. Zaman Z, Roche S, Fielden P. Plasma concentrations of vitamin E and carotenoids in Alzheimers disease. Age Ageing. 1992, 21:91-4.
89. Sims N, Bowen D, Neary D. Metabolic processes in Alzheimers disease adenine nucleotide content and production of (CO2)-C-14 from [U-C-14] glucose in vitro in human neocortex. J Neurochem. 1983, 41:1329-34.
90. Saito K, Elce J, Hamos J. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease - a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci USA. 1993, 90:2628-32.
91. Zhou Y, Richardson J, Mombourquette M. Free radical formation in autopsy samples of Alzheimer and control cortex. Neurosci Lett. 1995, 195:89-92.
92. Simic G, Lucassen P, Krsnik Z. nNOS expression in reactive astrocytes correlates with increased cell death related DNA damage in the hippocampus and entorhinal cortex in Alzheimer's disease. Exp Neurol. 2000, 165:12-26.
93. Conrad C, Marshall P, Talent J. Oxidized proteins in Alzheimer's plasma. Biochem Biophys Res Commun. 2000, 275:678-81.
94. Keller J, Markesbery W. Proteasome inhibition results in increased poly-ADP-ribosylation: Implications for neuron death. J Neurosci Res. 2000, 61:436-42.
95. Qiu J, Asai A, Chi S. Proteasome inhibitors induce cytochrome c-caspase-3-like protease-mediated apoptosis in cultured cortical neurons. J Neurosci. 2000, 20:259-65.
96. Pasquini L, Moreno M, Adamo A. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis and activates caspase-3 in cultured cerebellar granule cells. J Neurosci Res. 2000, 59:601-11.
97. Wagenknecht B, Hermisson M, Groscurth P. Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release. J Neurochem. 2000, 75:2288-97.
98. Taglialatela G, Kaufmann J, Trevino A. Central nervous system DNA fragmentation induced by the inhibition of nuclear factor kappa B. Neuroreport. 1998, 9:489-93.
99. Kitagawa H, Tani E, Ikemoto H. Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells. FEBS Lett. 1999, 443:181-6.
100. Marambaud P, Chevallier N, Barelli H. Proteasome contributes to the alpha-secretase pathway of amyloid precursor protein in human cells. J Neurochem. 1997, 68:698-703.
101. Skovronsky D, Pijak D, Doms R. A distinct ER/IC gamma-secretase competes with the proteasome for cleavage of APP. Biochemistry. 2000, 39:810-7.
102. Honda T, Yasutake K, Nihonmatsu N. Dual roles of proteasome in the metabolism of presenilin 1. J Neurochem. 1999, 72:255-61.
103. Ingano L, Lentini K, Kovacs I. Cytoplasmic presenilin aggregates in proteasome inhibitor-treated cells. Mol Basis Dementia. 2000, 920:259-60.
104. Kwak S, Masaki T, Ishiura S. Multicatalytic proteinase is present in Lewy bodies and neurofibrillary tangles in diffuse Lewy body disease brains. Neurosci Lett. 1991, 128:21-4.
105. Masaki T, Ishiura S, Sugita H. Multicatalytic proteinsase is associated with characteristic oval structures in cortical Lewy bodies - an immunocytochemical study with light and electron microscopy. J Neurol Sci. 1994, 122:127-34.
106. Canu N, Barbato C, Ciotti M. Proteasome involvement and accumulation of ubiquitinated proteins in cerebellar granule neurons undergoing apoptosis. J Neurosci. 2000, 20:589-99.
107. Favit A, Grimaldi M, Alkon D. Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway. J Neurochem. 2000, 75:1258-63.
108. Grilli M, Memo M. Possible role of NF-kappa B and p53 in the glutamate-induced pro-apoptotic neuronal pathway. Cell Death Differ. 1999, 6:22-7.
109. Mattson M, Culmsee C, Yu Z. Roles of nuclear factor kappa B in neuronal survival and plasticity. J Neurochem. 2000, 74:443-56.
110. Simons M, Keller P, De Strooper B. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA. 1998, 95:6460-4.
111. Refolo L, Pappolla M, Malester B. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Disease. 2000, 7:321-31.
112. Refolo L, Pappolla M, LaFrancois J. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Disease. 2001, 8:890-9.
113. Sparks D, Scheff S, Hunsaker J. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994, 126:88-94.
114. Sparks D. Intraneuronal beta-amyloid immunoreactivity in the CNS. Neurobiol Aging. 1996, 17:291-9.
115. Esiri M, Biddolph S, Morris C. Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry. 1998, 65:29-33.
116. Kountouras J, Tsolaki M, Gavalas E. Relationship between Helicobacter pylori infection and Alzheimer disease. Neurology. 2006, 66:938-40.
117. Itzhaki R, Wozniak M, Appelt D. Infiltration of the brain by pathogens causes Alzheimer's disease. Neurobiol Aging. 2004, 25:619-27.
118. Ball M. The essential lesion of Alzheimer disease: a surprise in retrospect. J Alzheimers Dis. 2006, 9:29-33.
119. Itzhaki R, Wozniak M. Herpes simplex virus type 1, apolipoprotein E, and cholesterol: a dangerous liaison in Alzheimer's disease and other disorders. Prog Lipid Res. 2006, 45:73-90.
120. Shipley S, Parkin E, Itzhaki R. Herpes simplex virus interferes with amyloid precursor protein processing. BMC Microbiol 10.1186/1471-2180-5-48, DOI
121. Satpute-Krishnan P, DeGiorgis J. Fast anterograde transport of herpes simplex virus: role for the amyloid precursor protein of Alzheimer's disease. Aging Cell. 2003, 2:305-18.
122. Wozniak M, Itzhaki R, Shipley S. Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Neurosci Lett. 2007, 429:95-100.
123. Heyman A, Wilkinson W, Stafford J. Alzheimer's disease: a study of epidemiological aspects. Ann Neurol. 1984, 15:335-41.
124. French L, Schuman L, Mortimer J. A case-control study of dementia of the Alzheimer type. Am J Epidemiol. 1985, 121:414-21.
125. Mortimer J, van Duijn C, Chandra V. Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991, 20:S28-35. EURODEM Risk Factors Research Group
126. Schofield P, Tang M, Marder K. Alzheimer's disease after remote head injury: an incidence study. J Neurol Neurosurg Psychiatry. 1997, 62:119-24.
127. Yamada M, Sasaki H, Mimori Y. Prevalence and risks of dementia in the Japanese population: RERF's adult health study Hiroshima subjects. Radiation Effects Research Foundation. J Am Geriatr Soc. 1999, 47:189-95.
128. Jamieson G, Maitland N, Wilcock G. Latent herpes simplex virus type 1 in normal and Alzheimer's disease brains. J Med Virol. 1991, 33:224-7.
129. Lin W, Shang D, Itzhaki R. Neurotropic viruses and Alzheimer disease. Interaction of herpes simplex type 1 virus and apolipoprotein E in the etiology of the disease. Mol Chem Neuropathol. 1996, 28:135-41.
130. Langenberg A, Corey L, Ashley R. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med. 1999, 341:1432-8.
131. Hill J, Steiner I, Matthews K. Statins lower the risk of developing Alzheimer's disease by limiting lipid raft endocytosis and decreasing the neuronal spread of Herpes simplex virus type 1. Med Hypotheses. 2005, 64:53-8.
132. Petryshyn R, Chen J, Danley L. Effect of interferon on protein translation during growth stages of 3T3 cells. Arch Biochem Biophys. 1996, 326:290-7.
133. Hiremath M, Mikhael A, Taylor L. Complex regulation of the Csk homologous kinase (Chk) by IL-4 family cytokines and IFN-gamma in human peripheral blood monocytes. Mol Immunol. 2004, 41:901-10.
134. Donev RM, Cole DS, Sivasankar B. p53 regulates cellular resistance to complement lysis through enhanced expression of CD59. Cancer Res. 2006, 66:2451-8.
135. Donev R, Newall A, Thome J. A role for SC35 and hnRNPA1 in the determination of amyloid precursor protein isoforms. Mol Psychiatry. 2007, 12:681-90.
136. Yamamoto M, Kiyota T, Horiba M. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol. 2007, 170:680-92.
137. Hardwicke M, Sandri-Goldin R. The herpes simplex virus regulatory protein ICP27 contributes to the decrease in cellular mRNA levels during infection. J Virol. 1994, 68:4797-810.
138. Bryant H, Wadd S, Lamond A. Herpes simplex virus IE63 (ICP27) protein interacts with spliceosome-associated protein 145 and inhibits splicing prior to the first catalytic step. J Virol. 2001, 75:4376-85.
139. Lindberg A, Kreivi J. Splicing inhibition at the level of spliceosome assembly in the presence of herpes simplex virus protein ICP27. Virology. 2002, 294:189-98.
140. Sciabica K, Dai Q, Sandri-Goldin R. ICP27 interacts with SRPK1 to mediate HSV splicing inhibition by altering SR protein phosphorylation. EMBO J. 2003, 22:1608-19.
141. Klajnert B, Cortijo-Arellano M, Cladera J. Influence of dendrimer's structure on its activity against amyloid fibril formation. Biochem Biophys Res Commun. 2006, 345:21-8.
142. Yanagisawa K. Cholesterol and amyloid beta fibrillogenesis. Subcell Biochem. 2005, 38:179-202.
143. Cummings J. Alzheimer's disease. N Engl J Med. 2004, 351:56-67.
144. Francis P, Palmer A, Snape M. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999, 66:137-47.
145. Cummings J, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology. 1996, 47:876-83.
146. Perry E, Gibson P, Blessed G. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci. 1977, 34:247-65.
147. Wilcock G, Esiri M, Bowen D. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci. 1982, 57:407-17.
148. Perry E, Tomlinson B, Blessed G. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J. 1978, 2:1457-9.
149. Wilkinson D, Francis P, Schwam E. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging. 2004, 21:453-78.
150. Katsuki H, Izumi Y, Zorumski C. Removal of extracellular calcium after conditioning stimulation disrupts long-term potentiation in the CA1 region of rat hippocampal slices. Neuroscience. 1997, 76:1113-9.
151. Lipton S. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx. 2004, 1:101-10.
152. Reisberg B, Doody R, Stöffler A. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003, 348:1333-41.
153. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999, 14:135-46.
154. Roberds S, Anderson J, Basi G. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet. 2001, 10:1317-24.
155. Fukumoto H, Rosene D, Moss M. Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol. 2004, 164:719-25.
156. Leung D, Abbenante G, Fairlie D. Protease inhibitors: current status and future prospects. J Med Chem. 2000, 43:305-41.
157. Hong L, Koelsch G, Lin X. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science. 2000, 290:150-3.
158. Asai M, Hattori C, Iwata N. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem. 2006, 96:533-40.
159. Ghosh A, Kumaragurubaran N, Hong L. Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation. Bioorg Med Chem Lett. 2008, 18:1031-6.
160. Hamada Y, Ohta H, Miyamoto N. Novel non-peptidic and small-sized BACE1 inhibitors. Bioorg Med Chem Lett. 2008, 18:1643-7.
161. Hussain I, Hawkins J, Harrison D. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J Neurochem. 2007, 100:802-9.
162. Wong P, Zheng H, Chen H. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature. 1997, 387:288-92.
163. Shen J, Bronson R, Chen D. Skeletal and CNS defects in presenilin-1-deficient mice. Cell. 1997, 89:629-39.
164. Selkoe D, Kopan R. Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci. 2003, 26:565-97.
165. Searfoss G, Jordan W, Calligaro D. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem. 2003, 278:46107-16.
166. Wong G, Manfra D, Poulet F. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004, 279:12876-82.
167. Siemers E, Quinn J, Kaye J. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006, 66:602-4.
168. Barten D, Guss V, Corsa J. Dynamics of [beta]-amyloid reductions in brain, cerebrospinal fluid, and plasma of [beta]-amyloid precursor protein transgenic mice treated with a [gamma]-secretase inhibitor. J Pharmacol Exp Ther. 2005, 312:635-43.
169. Anderson J, Holtz G, Baskin P. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol. 2005, 69:689-98.
170. Kopan R, Ilagan M. Gamma-secretase: proteasome of the membrane. Nat Rev Mol Cell Biol. 2004, 5:499-504.
171. Wolfe M. Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics. 2008, 5:391-8.
172. Tomita T. Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev Neurother. 2009, 9:661-79.
173. Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002, 360:23-33. MRC/BHF
174. Luchsinger J, Tang M, Shea S. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol. 2003, 60:203-8.
175. Laurin D, Masaki K, Foley D. Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia Aging Study. Am J Epidemiol. 2004, 159:959-67.
176. Miller Er, Pastor-Barriuso R, Dalal D. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005, 142:37-46.
177. Cummings J. The role of cholinergic agents in the management of behavioural disturbances in Alzheimer's disease. Int J Neuropsychopharmacol. 2000, 3:21-9.
178. Solomon P, Adams F, Silver A. Ginkgo for memory enhancement: a randomized controlled trial. JAMA. 2002, 288:835-40.
179. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003, 327:128.
180. in t' Veld B, Ruitenberg A, Hofman A. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001, 345:1515-21.
181. Zandi P, Anthony J, Hayden K. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology. 2002, 59:880-6.
182. Beard C, Waring S, O'Brien P. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin Proc. 1998, 73:951-5.
183. Aisen P, Schafer K, Grundman M. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003, 289:2819-26.
184. Van Gool W, Weinstein H, Scheltens P. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet. 2001, 358:455-60.
185. Aisen P. Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial. Acta Neurol Scand Suppl. 2000, 176:85-9.
186. Aisen P, Schmeidler J, Pasinetti G. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology. 2002, 58:1050-4.
187. Scharf S, Mander A, Ugoni A. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology. 1999, 53:197-201.
188. Thomas T, Rhodin J. Vascular actions of estrogen and Alzheimer's disease. Ann N Y Acad Sci. 2000, 903:501-9.
189. Koh K, Cardillo C, Bui M. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation. 1999, 99:354-60.
190. Gewurz H, Clark D, Cooper M. Effect of cobra venom-induced inhibition of complement activity on allograft and xenograft rejection reactions. Transplantation. 1967, 5:1296-303.
191. Maillard J, Zarco R. [Decomplementization by a factor extracted from cobra venom. Effect on several immune reactions of the guinea pig and rat]. Ann Inst Pasteur. 1968, 114:756-74.
192. Cochrane C, Müller-Eberhard H, Aikin B. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol. 1970, 105:55-69.
193. Phillips G. Studies on a hemolytic factor of cobra venom requiring a heat-labile serum factor. Biochim Biophys Acta. 1970, 201:364-74.
194. Müller-Eberhard H, Fjellström K. Isolation of the anticomplementary protein from cobra venom and its mode of action on C3. J Immunol. 1971, 107:1666-72.
195. Cooper N. Formation and function of a complex of the C3 proactivator with a protein from cobra venom. J Exp Med. 1973, 137:451-60.
196. Weiler J, Yurt R, Fearon D. Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin. J Exp Med. 1978, 147:409-21.
197. Baker P, Lint T, McLeod B. Studies on the inhibition of C56-induced lysis (reactive lysis). VI. Modulation of C56-induced lysis polyanions and polycations. J Immunol. 1975, 114:554-8.
198. Hughes-Jones N, Gardner B. The reaction between the complement subcomponent C1q, IgG complexes and polyionic molecules. Immunology. 1978, 34:459-63.
199. Almeda S, Rosenberg R, Bing D. The binding properties of human complement component C1q. Interaction with mucopolysaccharides. J Biol Chem. 1983, 258:785-91.
200. Weiler J. Polyions regulate the alternative amplification pathway of complement. Immunopharmacology. 1983, 6:245-55.
201. Weiler J, Edens R, Linhardt R. Heparin and modified heparin inhibit complement activation in vivo. J Immunol. 1992, 148:3210-5.
202. Edens R, Linhardt R, Bell C. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum. Immunopharmacology. 1994, 27:145-53.
203. Bergamaschini L, Rossi E, Storini C. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J Neurosci. 2004, 24:4181-6.
204. Asghar S. Pharmacological manipulation of complement system. Pharmacol Rev. 1984, 36:223-44.
205. Hong K, Kinoshita T, Kitajima H. Inhibitory effect of K-76 monocarboxylic acid, an anticomplementary agent, on the C3b inactivator system. J Immunol. 1981, 127:104-8.
206. Miyazaki W, Izawa T, Nakano Y. Effects of K-76 monocarboxylic acid, an anticomplementary agent, on various in vivo immunological reactions and on experimental glomerulonephritis. Complement. 1984, 1:134-46.
207. Englberger W, Hadding U, Etschenberg E. Rosmarinic acid: a new inhibitor of complement C3-convertase with anti-inflammatory activity. Int J Immunopharmacol. 1988, 10:729-37.
208. Sahu A, Rawal N, Pangburn M. Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b. Biochem Pharmacol. 1999, 57:1439-46.
209. Ling M, Piddlesden S, Morgan B. A component of the medicinal herb ephedra blocks activation in the classical and alternative pathways of complement. Clin Exp Immunol. 1995, 102:582-8.
210. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta. 1981, 661:342-5.
211. Inagi R, Miyata T, Maeda K. FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a. Immunol Lett. 1991, 27:49-52.
212. Ino Y, Sato T, Koshiyama Y. Effects of FUT-175, a novel synthetic protease inhibitor, on the development of adjuvant arthritis in rats and some biological reactions dependent on complement activation. Gen Pharmacol. 1987, 18:513-6.
213. Miyagawa S, Shirakura R, Matsumiya G. Prolonging discordant xenograft survival with anticomplement reagents K76COOH and FUT175. Transplantation. 1993, 55:709-13.
214. Holland M, Morikis D, Lambris J. Synthetic small-molecule complement inhibitors. Curr Opin Investig Drugs. 2004, 5:1164-73.
215. Morgan B, Harris C. Complement therapeutics; history and current progress. Mol Immunol. 2003, 40:159-70.
216. Weisman H, Bartow T, Leppo M. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 1990, 249:146-51.
217. Lazar H, Keilani T, Fitzgerald C. Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference. Circulation 2007, 116:I83-8.
218. Lazar H, Bokesch P, van Lenta F. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 2004, 110:II274-9.
219. Harris C, Williams A, Linton S. Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo. Clin Exp Immunol. 2002, 129:198-207.
220. Smith G, Smith R. Membrane-targeted complement inhibitors. Mol Immunol. 2001, 38:249-55.
221. Song H, He C, Knaak C. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest. 2003, 111:1875-85.
222. Carrier M, Ménasché P, Levy J. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2006, 131:352-6.
223. Brodsky R, Young N, Antonioli E. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008, 111:1840-7.
224. Kaplan M. Eculizumab (Alexion). Curr Opin Investig Drugs. 2002, 3:1017-23.
225. Bora N, Kaliappan S, Jha P. CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration. J Immunol. 2007, 178:1783-90.
226. Zhang H, Yu J, Bajwa E. Targeting of functional antibody-CD59 fusion proteins to a cell surface. J Clin Invest. 1999, 103:55-61.
227. Schenk D, Barbour R, Dunn W. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999, 400:173-7.
228. Janus C, Pearson J, McLaurin J. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000, 408:979-82.
229. DeMattos R, Bales K, Cummins D. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2001, 98:8850-5.
230. Dodart J, Bales K, Gannon K. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002, 5:452-7.
231. Wisniewski T, Frangione B. Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. Brain Pathol. 2005, 15:72-7.
232. Bayer A, Bullock R, Jones R. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology. 2005, 64:94-101.
233. Pride M, Seubert P, Grundman M. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis. 2008, 5:194-6.
234. Orgogozo J, Gilman S, Dartigues J. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003, 61:46-54.
235. Boche D, Nicoll J. The role of the immune system in clearance of Abeta from the brain. Brain Pathol. 2008, 18:267-78.
236. Boche D, Zotova E, Weller R. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain. 2008, 131:3299-310.
237. Bombois S, Maurage C, Gompel M. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch Neurol. 2007, 64:583-7.
238. Masliah E, Hansen L, Adame A. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005, 64:129-31.
239. Nicoll J, Barton E, Boche D. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006, 65:1040-8.
240. Hock C, Konietzko U, Papassotiropoulos A. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med. 2002, 8:1270-5.
241. Nicoll J, Wilkinson D, Holmes C. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003, 9:448-52.
242. Webster S, Galvan M, Ferran E. Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q. J Immunol. 2001, 166:7496-503.
243. Sadowski M, Wisniewski T. Disease modifying approaches for Alzheimer's pathology. Curr Pharm Des. 2007, 13:1943-54.
244. Gilman S, Koller M, Black R. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005, 64:1553-62.
245. Holmes C, Boche D, Wilkinson D. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008, 372:216-23.
246. Wisniewski T. AD vaccines: conclusions and future directions. CNS Neurol Disord Drug Targets. 2009, 8:160-6.
247. Rakover I, Arbel M, Solomon B. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels. Neurodegener Dis. 2007, 4:392-402.
248. Wilk S, Chen W. Synthetic peptide-based activators of the proteasome. Mol Biol Rep. 1997, 24:119-24.
249. Wilk S, Chen W, Magnusson R. Modulation of the PA28 alpha-20S proteasome interaction by a peptidyl alcohol. Arch Biochem Biophys. 1999, 362:283-90.
250. Demena I, Mahillo E, Arribas J. Kinetic mechanism of activation by cardiolipin (diphosphatidylglycerol) of the rat liver multicatalytic proteinase. Biochem J. 1993, 296:93-7.
251. Xie Y, Varshavsky A. RPN4 is a ligand, substrate, and transcriptional regulator of the 26S proteasome: A negative feedback circuit. Proc Natl Acad Sci USA. 2001, 98:3056-61.
252. Rockenstein E, Torrance M, Mante M. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. J Neurosci Res. 2006, 83:1252-61.
253. Rockenstein E, Mallory M, Mante M. Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease. J Neural Transm Suppl. 2002, 62:327-36.
254. Rüther E, Ritter R, Apecechea M. Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy. J Neural Transm. 2000, 107:815-29.
255. Melnikova I. Therapies for Alzheimer's disease. Nat Rev Drug Discov. 2007, 6:341-2.
256. Lleó A, Greenberg S, Growdon J. Current pharmacotherapy for Alzheimer's disease. Annu Rev Med. 2006, 57:513-33.
257. Bureeva S, Andia-Pravdivy J, Kaplun A. Drug design using the example of the complement system inhibitors' development. Drug Discov Today. 2005, 10:1535-42.
258. Makrides S. Therapeutic inhibition of the complement system. Pharmacol Rev. 1998, 50:59-87.